GlassScriptPhysician profile
Youssef B Ghaly
NPI 1770580334
$11,039.10
in general payments reported to CMS, 2019-2025
36 companies · $699 in 2025
The $699 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $1,485 · 2021: $3,136 · 2022: $1,446 · 2023: $1,388 · 2024: $1,443 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,736.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,380.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,361.49 | 2020-2021 | |
| Abbvie INC. | $1,253.65 | 2021-2025 | |
| Lilly USA, LLC | $944.10 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $655.04 | 2019-2025 | |
| Amgen INC. | $469.89 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $398.46 | 2019-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $270.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $267.60 | 2020-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.74 | 2019-2022 | |
| Kaleo, INC. | $194.01 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $193.63 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $190.85 | 2022 | |
| Merck Sharp & Dohme LLC | $173.16 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $153.67 | 2021-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $148.81 | 2019-2020 | |
| Horizon Therapeutics Plc | $112.44 | 2019-2022 | |
| Merz North America, INC. | $106.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.91 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $78.23 | 2021-2022 | |
| Vivus LLC | $63.99 | 2022 | |
| Abbott Laboratories | $63.69 | 2022 | |
| Idorsia Pharmaceuticals US INC | $60.94 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $54.08 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.99 | 2020-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $46.48 | 2020-2021 | |
| Optinose US, INC. | $45.50 | 2022 | |
| Boston Scientific Corporation | $44.60 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $43.71 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $26.88 | 2023 | Qelbree |
| Pharming Healthcare, INC. | $25.94 | 2024 | Ruconest |
| Grifols USA, LLC | $20.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.24 | 2019 | |
| Ibsa Pharma INC. | $16.69 | 2021 | |
| Alfasigma USA, INC. | $15.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Ghaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.